Ex-FDA chief Stephen Hahn lands an­oth­er new gig, this time as CEO of a can­cer test­ing start­up

Since leav­ing the FDA’s top post last Jan­u­ary, Steve Hahn has been busy, jump­ing be­tween mul­ti­ple in­dus­try po­si­tions thanks to Flag­ship Pi­o­neer­ing, and most re­cent­ly tak­ing the helm at a start­up fo­cused on the de­tec­tion of ear­ly can­cer with a sim­ple blood test.

Hahn’s new com­pa­ny, known as Har­bin­ger Health, will re­ceive $50 mil­lion from Flag­ship to use a pro­pri­etary plat­form com­bin­ing AI and ma­chine learn­ing to po­ten­tial­ly cre­ate an en­tire­ly new par­a­digm for can­cer di­ag­no­sis, en­abling ear­ly ther­a­peu­tic in­ter­ven­tions or pre­ven­tion. Hahn’s pri­or work as chief med­ical ex­ec­u­tive of the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter will like­ly in­form his new role, where he’s serv­ing as a Flag­ship CEO-part­ner as well as CEO of Har­bin­ger.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER